Unlock instant, AI-driven research and patent intelligence for your innovation.

Nanogene drug targeting interleukin-22 for treating liver injury

A technology of interleukin and gene medicine, applied in the field of biopharmaceuticals, to achieve the effect of reducing immunogenicity

Inactive Publication Date: 2019-01-18
FUDAN UNIV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Studies have shown that although interleukin-22 has made great progress in the application of disease treatment, it still faces great challenges as a safe and effective drug
Interleukin-22 receptors are widely distributed in normal pancreas, liver, small intestine, colon, kidney and other tissues [Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov.2014; 13:21-38.; Moore KW, de WaalMalefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol.2001; 19:683-765.]; Interleukin 22 can cause systemic biological effects, so it is not suitable for intervention and treatment of liver diseases such as autoimmune liver disease, drug-induced liver injury, viral hepatitis, alcoholic liver disease, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanogene drug targeting interleukin-22 for treating liver injury
  • Nanogene drug targeting interleukin-22 for treating liver injury
  • Nanogene drug targeting interleukin-22 for treating liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1. Preparation of interleukin 22 and apolipoprotein AI recombinant fusion gene

[0040] Obtaining the gene encoding interleukin 22: human peripheral blood mononuclear cells were cultured in RPMI1640 medium containing 5 μg / ml lipopolysaccharide for 18 hours, RNA was extracted with Trizol, and RNA was reversed with a reverse transcription kit , finally obtain cDNA;

[0041] Use the cDNA obtained by reverse transcription as a template, and use Primer to design primers, where the upstream primer is: 5'-agtt CATATg gcgcccatcagctcccact-3',) where the underline is the NdeI restriction site; the downstream primer is: 5'-atcg GGATCC aatgcaggcatttctcagag-3', where the underline is the BamHI restriction site. Primers were synthesized by Shanghai Sangon Bioengineering Company;

[0042] The interleukin 22 gene containing NdeI and BamHI restriction sites was cloned by PCR method, and detected by 1% agarose gel electrophoresis. The size of the PCR product was about 500bp,...

Embodiment 2

[0046] Example 2, construction of interleukin 22 and apolipoprotein AI recombinant fusion gene expression vector

[0047] Take pVAX1 expression vector and pMD19-T-interleukin 22 encoding gene plasmid, use NdeI and BamHI restriction endonucleases to carry out double enzyme digestion, and use 1% agarose gel electrophoresis to separate the digested products, use gel recovery kit Recover the target fragment, among which the pVAX1 expression vector recovers a fragment of about 3000bp, and the pMD19-interleukin 22 recovers a fragment of about 500bp;

[0048] The ligation reaction is carried out under the catalysis of T4 DNA ligase. The molar ratio of pET24b expression vector restriction fragment and interleukin 22 gene target fragment is about 1:3. The ligation reaction system is 25ul, including T4 ligase 1ul, 10XT4 DNA ligase buffer 2.5ul solution, connect overnight at 16°C;

[0049] The ligation product was transformed into competent Escherichia coli Top10, spread on a kanamycin-...

Embodiment 3

[0053] Example 3pIA in vitro and in vivo expression experiments

[0054] HEK-293T cells were planted in a six-well plate, and when the cell fusion rate reached 70-80%, 2 and 4 μg of pIA were transfected with lipofectamine2000, respectively. The cells continued to be cultured for 24 hours. After the cells were harvested and lysed with a cell lysate, they were quantified with a BCA kit, and Western blot was used to detect the contents of interleukin 22 and ApoA I in the cells (such as figure 1 B, C shown);

[0055] HEK-293T cells were planted on sterilized coverslips. When the cell confluence rate reached 70%, 4 μg of pIA was transfected with lipofectamine 2000. After the cells were cultured overnight, the medium was discarded and replaced with 4% paraformaldehyde After fixing for 15 minutes, the cells were washed 3 times with PBS, then permeabilized with a solution containing 0.5% Triton X-100 for 20 minutes, and washed 3 times with PBS. Cells were then blocked with FBS for 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A nanometer gene therapy drug based on targeting interleukin-22 for treating liver injury and its preparation method are disclosed. The nanometer gene therapy drug is prepared from DOTAP / Cholesterol wrapped IL-22 / ApoA I fusion protein expression vector was prepare by membrane hydration method. IL-Expected to be expressed in vivo in the nano-drug-22 / ApoA I fusion protein, recognize SR-BI ligand positive expression of hepatocytes, the preparation of liposIA protein molecules in vivo expression can overcome the shortcomings of short half-life and can achieve the reduction of immunogenicity of interleukin-22. The nano-drug has the characteristics of high stability, controllable quality and relative safety. And can be further prepared into medicine for resisting hepatocyte injury.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and relates to a nano-gene drug for treating liver damage, in particular to a nano-gene drug for treating liver damage based on targeting interleukin 22, and a preparation method thereof. The nano-gene drug can be used for treating drug-induced liver injury. Injury, autoimmune liver disease, viral hepatitis, alcoholic liver, hepatocellular carcinoma and other liver diseases and diabetes. Background technique [0002] The prior art discloses that interleukin 22 (Interleukin 22), as a cytokine of the interleukin 10 family, can not only produce special cell chemokines and antibacterial proteins, but also can up-regulate certain cell proliferation genes, anti-apoptotic Protein and antioxidant factors [Sertorio M, Hou X, Carmo RF, Dessein H, Cabantous S, Abdelwahed M, et al. Interleukin-22 and IL-22binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infectio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/20A61K48/00A61K47/18A61K47/28A61P1/16A61P37/02A61P31/14A61P31/20A61P35/00A61P3/10C12N15/63
CPCA61K38/20A61K47/186A61K47/28A61K47/42A61K48/0008C12N15/63
Inventor 鞠佃文陈伟
Owner FUDAN UNIV